Literature DB >> 10388539

Antisense inhibition of protein kinase Calpha reverses the transformed phenotype in human lung carcinoma cells.

X Y Wang1, E Repasky, H T Liu.   

Abstract

The protein kinase C (PKC) family, which functions through serine/threonine kinase activity, is involved in signal transduction pathways necessary for cell proliferation and differentiation. Its critical role in processes relevant to neoplastic transformation and tumor invasion renders PKC a potentially suitable target for anticancer therapy. To explore whether antisense blocking of PKCalpha would inhibit the neoplastic properties in tumor cells, human lung carcinoma LTEPa-2 cells were transfected with a recombinant plasmid, pXJ41-CKPalpha, with PKCalpha cDNA inserted in the antisense orientation. In LT.AS4 cell clones stably expressing antisense PKCalpha mRNA, the amounts of PKCalpha protein and total PKC activity were decreased when compared to control cells. The expression of antisense PKCalpha markedly inhibited the cell proliferation rate, colony forming efficiency in soft agar, and tumorigenecity in nude mice. Furthermore, the mRNA levels of oncogenes (Ha-ras, c-jun, and c-fos) were seen to decrease to varying degrees. Reduced DNA binding activity of transcription factor AP-1 was also observed using gel shift analysis, suggesting that one major molecular mechanism by which PKCalpha can exert its effects on cell growth and transformation is through regulation of AP-1 transcription factor activity. Taken together, these data provide evidence for the ability of antisense PKCalpha expression to reverse the transformed phenotype of human lung carcinoma cells and support the development of PKCalpha inhibitors for the clinical treatment of cancers. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10388539     DOI: 10.1006/excr.1999.4529

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  10 in total

1.  Antisense expression of PKCalpha improved sensitivity of SGC7901/VCR cells to doxorubicin.

Authors:  Da-Long Wu; Feng-Ying Sui; Cheng Du; Cheng-Wen Zhang; Bin Hui; Shui-Ling Xu; Huan-Zhang Lu; Guo-Jie Song
Journal:  World J Gastroenterol       Date:  2009-03-14       Impact factor: 5.742

2.  Gene expression patterns and gene copy number changes in dermatofibrosarcoma protuberans.

Authors:  Sabine C Linn; Rob B West; Jonathan R Pollack; Shirley Zhu; Tina Hernandez-Boussard; Torsten O Nielsen; Brian P Rubin; Rajiv Patel; John R Goldblum; David Siegmund; David Botstein; Patrick O Brown; C Blake Gilks; Matt van de Rijn
Journal:  Am J Pathol       Date:  2003-12       Impact factor: 4.307

3.  Protein kinase C alpha-dependent signaling mediates endometrial cancer cell growth and tumorigenesis.

Authors:  James M Haughian; Elaine M Reno; Alicia M Thorne; Andrew P Bradford
Journal:  Int J Cancer       Date:  2009-12-01       Impact factor: 7.396

4.  Role of caveolin 1, E-cadherin, Enolase 2 and PKCalpha on resistance to methotrexate in human HT29 colon cancer cells.

Authors:  Elisabet Selga; Cristina Morales; Véronique Noé; Miguel A Peinado; Carlos J Ciudad
Journal:  BMC Med Genomics       Date:  2008-08-11       Impact factor: 3.063

5.  Elevated H3K27me3 levels sensitize osteosarcoma to cisplatin.

Authors:  Chao He; Jian Sun; Chao Liu; Yuhang Jiang; Yongqiang Hao
Journal:  Clin Epigenetics       Date:  2019-01-16       Impact factor: 6.551

Review 6.  Protein Kinase C as a Therapeutic Target in Non-Small Cell Lung Cancer.

Authors:  Mohammad Mojtaba Sadeghi; Mohamed F Salama; Yusuf A Hannun
Journal:  Int J Mol Sci       Date:  2021-05-24       Impact factor: 5.923

7.  Gelsolin suppresses tumorigenicity through inhibiting PKC activation in a human lung cancer cell line, PC10.

Authors:  N Sagawa; H Fujita; Y Banno; Y Nozawa; H Katoh; N Kuzumaki
Journal:  Br J Cancer       Date:  2003-02-24       Impact factor: 7.640

8.  Protein kinase C: an attractive target for cancer therapy.

Authors:  Barbara Marengo; Chiara De Ciucis; Roberta Ricciarelli; Maria A Pronzato; Umberto M Marinari; Cinzia Domenicotti
Journal:  Cancers (Basel)       Date:  2011-02-01       Impact factor: 6.639

9.  Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.

Authors:  Collin M Blakely; Thomas B K Watkins; Wei Wu; Beatrice Gini; Jacob J Chabon; Caroline E McCoach; Nicholas McGranahan; Gareth A Wilson; Nicolai J Birkbak; Victor R Olivas; Julia Rotow; Ashley Maynard; Victoria Wang; Matthew A Gubens; Kimberly C Banks; Richard B Lanman; Aleah F Caulin; John St John; Anibal R Cordero; Petros Giannikopoulos; Andrew D Simmons; Philip C Mack; David R Gandara; Hatim Husain; Robert C Doebele; Jonathan W Riess; Maximilian Diehn; Charles Swanton; Trever G Bivona
Journal:  Nat Genet       Date:  2017-11-06       Impact factor: 38.330

10.  MED13L integrates Mediator-regulated epigenetic control into lung cancer radiosensitivity.

Authors:  Nasha Zhang; Yemei Song; Yeyang Xu; Jiandong Liu; Yue Shen; Liqing Zhou; Jinming Yu; Ming Yang
Journal:  Theranostics       Date:  2020-07-23       Impact factor: 11.556

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.